Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74878 | 0.86 | SLC7A5 (0.55) | MEN1KMT2AALDH1A1HPGDCYP4F2 | |
| SCHEMBL30692683 | 0.86 | SLC7A5 (0.55) | MEN1KMT2AALDH1A1HPGDCYP4F2 | |
| SCHEMBL16702357 | 0.84 | MEN1 (0.48) | SRCMEN1KMT2AALDH1A1HTR2A | |
| SCHEMBL16709809 | 0.83 | SMN1; SMN2 (0.54) | MEN1KMT2ASMN1; SMN2HDAC1HPGD | |
| SCHEMBL16709816 | 0.78 | MAOB (0.48) | SRCMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13866770 | 0.78 | SMN1; SMN2 (0.59) | SRCSMN1; SMN2ALDH1A1HDAC1FFAR1 | |
| SCHEMBL5046368 | 0.77 | TLR7 (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1HDAC1 | |
| SCHEMBL5725928 | 0.77 | SMN1; SMN2 (0.65) | MEN1KMT2ASMN1; SMN2ALDH1A1HDAC1 | |
| SCHEMBL378218 | 0.76 | CYP4F2 (0.63) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP4F2 | |
| SCHEMBL17070607 | 0.76 | CYP4F2 (0.63) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531721-B | Fused tricyclic pyrazole derivatives for modulating farnesoid X receptors | 诺华股份有限公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-3288948-B1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2019-11-20 | — | — | EP | disclosed |
| EP-3288948-B1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-10351576-B2 | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors | NOVARTIS AG (CH) | 2019-07-16 | — | — | US | disclosed |
| US-10351576-B2 | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors | NOVARTIS AG (CH) | 2019-07-16 | — | — | US | disclosed |
| US-20180298018-A1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2018-10-18 | — | — | US | disclosed |
| WO-2016174616-A1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298018-A1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR FARNESOID X RECEPTORS | NR1H4, FXR1, GPBAR1 | SRC 948/4885MEN1 3858/4885KMT2A 4529/4885 |
| US-10351576-B2 | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors | NR1H4, FXR1, GPBAR1 | SRC 948/4885MEN1 3858/4885KMT2A 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.